MedTrace Logo

Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus

NCT05417880 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 340

Last updated 2022-06-14

No results posted yet for this study

Summary

The main purpose of the VETA trial is to verify the potential beneficial effects of the combination of micronutrients namely Vitamin D3 and K2 in combination with oral antihyperglycemic Empagliflozin in Diabetes Mellitus

Conditions

Interventions

DRUG

Oral Hypoglycemic Agents,Oral

Control group with routine current oral hypoglycemic agents for 3-6 months

DRUG

Voreta

Empagliflozin 10 mg oral tablets Once Daily for 3-6 months

DRUG

Voreta plus SunnyD PRO

Empagliflozin 10 mg oral tablets + Vitamin D3 ( 2000 IU ) + Vitamin K2 ( 100 mcg) Once Daily for 3-6 months

Sponsors & Collaborators

  • University of Health Sciences Lahore

    collaborator OTHER

  • Scotmann Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Javed Akram, MRCP,FRCP · University of Health Sciences Lahore

  • Zaman Shaikh, MRCP,MSc · Sir Syed Medical hospital, Khi College of Sciences & Qayyumabad,Khi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-31
Primary Completion
2023-02-28
Completion
2023-06-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05417880 on ClinicalTrials.gov